Testosterone cipionate (Depo-Testosterone) injections: Supply issue
Testosterone cipionate injections 100 mg per ml, 10 ml vial will be out of stock from late October 2021 until November 2022 (pharmacode: 741264).
8 September 2022: Alternative product listed
Reason for the out of stock of Depo-Testosterone
Pfizer notified Pharmac of a supply interruption for their Depo-Testosterone injection. The interruption is caused by manufacturing constraints in the USA. The site that makes Depo-Testosterone is being used to make COVID-19 related products. This has meant that they have had to reduce the volume of other medicines they make at this site.
Pfizer have contacted clinicians and the market to advise them of this issue.
Supply issue with Sustanon Ampoules (pharmacode 2172011)
Due to the additional demand placed on Sustanon Ampoules by the Depo-Testosterone supply issue, there is now limitd stock of the Sustanon Ampoules.
We understand that Depo-Testosterone will be unavailable between late October 2021 and November 2022.
Pharmac has secured a section 29 alternative brand of testosterone inj 100 mg per ml. The alternative will be listed on the Pharmaceutical Schedule from 9 September 2022. We are working with the supplier to confirm stock availability dates and will update this page as further details become available.
- Chemical: Testosterone cipionate
- Presentation: inj 100 mg per ml, 10 ml vial
- Brand: Taro-Testosterone
- Pack size: 1
- Subsidy: $393.00
- Pharmacode: 2645149
RxOne users: the listings will be automatically updated by RxOne from the effective date.
TONIQ users: the listings will automatically be updated in Toniq medicine databases from the effective date.
Online Schedule: listing will not appear until the update for October is loaded.
Please note that Sector Operations Group will be unable to process claims for September 2022 dispensing of the above listings. Pharmacies can either:
- hold these claims until October 2022 OR
- reclaim them in October 2022 when they are rejected for payment in September 2022 claims.
Prescribing and supplying a medicine under section 29
Section 29 of the Medicines Act allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – e.g., doctors.
We know supplying a medicine under section 29 is not ideal. This is the only alternative available to ensure people can continue to access treatment.
We apologise for any inconvenience this causes.
People who receive Depo-Testosterone
If you currently receive testosterone cipionate injections, you will need to talk to your prescriber about which alternative treatment is best for you.
We know that changing treatments is not ideal. We are sorry about any inconvenience caused by this supply issue.
Who to contact
If you have any questions about Depo-Testosterone, call Pfizer Customer Services on 0800 736 363
If you receive Depo-Testosterone, talk to the person who prescribed the treatment. They know you and your clinical circumstances best and can advise on the best alternative for you.
If you have questions about the funding of testosterone injections, email email@example.com